Physician profile
Tina E Abraham
NPI 1215376108
$833,570.01
in general payments reported to CMS, 2019-2025
50 companies · $126K in 2025
The $126K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $33K · 2021: $73K · 2022: $164K · 2023: $203K · 2024: $232K · 2025: $126K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $421K · Travel and Lodging: $65K · Consulting Fee: $53K · Food and Beverage: $21K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $421,184.67 |
| Travel and Lodging | $65,359.96 |
| Consulting Fee | $53,068.61 |
| Food and Beverage | $21,314.09 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $436,185.30 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $200,944.22 | 2019-2025 | Dupixent |
| Genzyme Corporation | $107,907.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $49,330.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $34,019.21 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $728.97 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Csl Behring | $436.52 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Adma Biomanufacturing LLC | $408.86 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.27 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $353.93 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $238.89 | 2019-2025 | Xolair |
| Optinose US, INC. | $212.94 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $197.98 | 2023-2024 | |
| Mylan Specialty L.P. | $185.74 | 2020-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $169.56 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $166.86 | 2020-2022 | |
| Abbvie INC. | $149.15 | 2023-2024 | Avycaz |
| Novo Nordisk INC | $121.91 | 2021 | |
| Galderma Laboratories, L.P. | $117.91 | 2024-2025 | Nemluvio |
| Harmony Biosciences LLC | $116.65 | 2022-2024 | Wakix |
| Novartis Pharmaceuticals Corporation | $107.26 | 2019-2025 | |
| Leo Pharma INC. | $105.69 | 2022-2024 | Adbry |
| Pfizer INC. | $87.41 | 2020-2022 | |
| Kaleo, INC. | $80.62 | 2020-2023 | Auvi-Q |
| Pulmonx Corporation | $76.91 | 2022-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| United Therapeutics Corporation | $66.46 | 2021-2023 | Tyvaso |
| Electromed, INC. | $63.71 | 2022-2023 | Smartvest |
| Biocryst US Sales Co., LLC | $54.74 | 2023-2024 | Orladeyo |
| Insmed, INC. | $52.95 | 2021-2025 | Brinsupri, Arikayce |
| Octapharma USA, INC. | $51.60 | 2023-2024 | Panzyga |
| Viatris Specialty LLC | $47.63 | 2025 | Yupelri |
| Lilly USA, LLC | $41.31 | 2024-2025 | Ebglyss |
| Covis Pharma Gmbh | $37.14 | 2022 | |
| Circassia INC. | $30.87 | 2019 | |
| Vapotherm INC | $27.42 | 2022 | |
| Ionis Pharmaceuticals, INC. | $26.07 | 2025 | |
| Shire North American Group INC | $23.47 | 2019 | |
| Hospira, INC. | $23.44 | 2025 | |
| Mallinckrodt Hospital Products INC. | $22.19 | 2020 | |
| Merck Sharp & Dohme LLC | $20.59 | 2023 | |
| Advanced Respiratory, INC | $17.87 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.65 | 2019 | |
| Mayne Pharma Commercial LLC | $17.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.16 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.33 | 2023 | Horizant |
| Ibsa Pharma INC. | $15.09 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.98 | 2019 | |
| Hikma Pharmaceuticals USA | $13.58 | 2023 | Ryaltris |
| Janssen Pharmaceuticals, INC | $13.53 | 2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.